Dompe receives orphan drug status for neurotrophic keratitis treatment

The U.S. Food and Drug Administration has granted orphan drug designation for a recombinant human nerve growth factor-based treatment.Recombinant human nerve growth factor (rhNGF, Dompe) is indicated for the treatment of neurotrophic keratitis, a corneal disease that impacts fewer than 1 in 5,000 people, according to a press release.

Full Story →